Nectin-4 的基因表达及其在犬原发性肺腺癌中的临床意义。

Gene expression of Nectin-4 and its clinical significance in dogs with primary lung adenocarcinoma.

机构信息

Laboratory of Veterinary Surgery, Department of Veterinary Medicine, College of Bioresource Sciences, Nihon University, Fujisawa, Japan.

Laboratory Animal Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

出版信息

Vet Med Sci. 2022 Sep;8(5):1922-1929. doi: 10.1002/vms3.895. Epub 2022 Jul 29.

DOI:10.1002/vms3.895

PMID:35905293

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9514464/

Abstract

BACKGROUND

Canine primary lung adenocarcinoma (CPLA) is suspected by radiography or computed tomography; however, since there are no tumour markers, early diagnosis is difficult, and the prognosis is poor due to increased tumour volume. Nectin-4 has been reported to be expressed in human lung, ovarian, and pancreatic cancers and promotes tumour growth. It has been reported to be a tumour marker and prognostic factor, and oncolytic virotherapy is being investigated using nectin-4 as a therapeutic target.

OBJECTIVES

The purpose of this study was to investigate the expression of Nectin-4 in CPLA and its clinical significance in dogs with pulmonary adenocarcinomas.

METHODS

The relationships between Nectin-4 expression and signalling, tumour volume, tumour weight, and prognosis were analyzed in 34 CPLA patients.

RESULTS

The expression of canine Nectin-4 (high Nectin-4) was found in 25 of 34 cases (73%), and Nectin-4 expression levels did not show any significant associations with gender, body weight, and tumour stage. However, there was a significant positive correlation between Nectin-4 expression and tumour volume (r = 0.623, p < 0.05) and tumour weight (r = 0.735, p < 0.05). Regarding prognosis, the median survival time was 427 days in high Nectin-4 cases and 420 days in cases with no Nectin-4 expression.

CONCLUSION

Our study demonstrated that Nectin-4 is highly expressed in CPLA. In addition, nectin-4 might be a tumour growth factor in CPLA and thus is a promising biomarker for CPLA. Further investigations on nectin-4 in CPLA are warranted for its diagnosis and novel targets for oncolytic virotherapy.

摘要

背景

犬原发性肺腺癌（CPLA）可通过放射学或计算机断层扫描怀疑；然而，由于没有肿瘤标志物，早期诊断较为困难，并且由于肿瘤体积增加，预后较差。 nectin-4 已被报道在人类肺癌、卵巢癌和胰腺癌中表达，并促进肿瘤生长。它已被报道为肿瘤标志物和预后因素，并且正在使用 nectin-4 作为治疗靶标进行溶瘤病毒治疗的研究。

目的

本研究旨在探讨 Nectin-4 在 CPLA 中的表达及其在犬肺腺癌中的临床意义。

方法

分析了 34 例 CPLA 患者的 Nectin-4 表达与信号、肿瘤体积、肿瘤重量和预后之间的关系。

结果

在 34 例病例中，有 25 例（73%）发现犬 Nectin-4（高 Nectin-4）表达，并且 Nectin-4 表达水平与性别、体重和肿瘤分期均无显著相关性。然而，Nectin-4 表达与肿瘤体积（r = 0.623，p < 0.05）和肿瘤重量（r = 0.735，p < 0.05）之间存在显著正相关。关于预后，高 Nectin-4 病例的中位生存时间为 427 天，无 Nectin-4 表达病例的中位生存时间为 420 天。